Abstracts tagged "T Cell"

Abstract Number: 0090 • ACR Convergence 2023
Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis
Addison Pacheco¹, Michael Tang¹, Sinead Maguire², Melissa Lim¹, Fataneh Tavasolian³, Zoya Qaiyum⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…
Abstract Number: 0800 • ACR Convergence 2023
CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis
Shozo Ohtsuki¹, Jose Morales², Yuki Sato², Chenyao Wang², Matthew Koster³, Kenneth Warrington³, Gerald J. Berry⁴, Jorg Goronzy³ and Cornelia M. Weyand⁵, ¹Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: In Giant Cell Arteritis (GCA), granulomatous infiltrates occupy the vessel wall and elicit maladaptive vascular remodeling with intimal hyperplasia. The major cell types of…
Abstract Number: 1382 • ACR Convergence 2023
Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome
Qinghong Liu¹ and Jing He², ¹Peking University People's Hospital, Beijing, China, ²Peking University People’s Hospital, Beijing, China
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by systemic involvement and lacks effective treatment options. The Janus kinase (JAK) pathway plays a…
Abstract Number: 2582 • ACR Convergence 2023
Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA
Hideto Takada¹, Kristen Demoruelle¹, Kevin Deane¹, Shohei Nakamura², Yasuhiro Katsumata³, Katsunori Ikari², Jane Buckner⁴, William H. Robinson⁵, Jennifer Seifert¹, Marie Feser¹, LauraKay Moss¹, Jill Norri⁶, Masayoshi Harigai³, Elena Hsieh¹, Michael Holer¹ and Yuko Okamoto², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Stanford University, Palo Alto, CA, ⁶Colorado School of Public Health, Denver, CO

Background/Purpose: Production of ACPA following T and B cell interactions is a hallmark of ACPA+ RA. Recently identified peripheral helper T (Tph) cells have B…
Abstract Number: 0072 • ACR Convergence 2023
Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons
Marie Naingeon¹, Samuel Bitoun², Matthieu roulleaux Dugage¹, Caroline de Oliveira¹, Caroline Berthot¹, Xavier Mariette³, Nathalie Chaput¹ and Gaetane Nocturne⁴, ¹LIO, Department of Medicine, Gustave Roussy Université Paris Saclay, Villejuif, France, ²CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ³Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁴APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Immunosenescence is a global remodeling of immune functions that has been first described with aging. It can also occur in pathologies associated with chronic…
Abstract Number: 0092 • ACR Convergence 2023
Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion
Michael Tang¹, Zoya Qaiyum², Melissa Lim¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Sustained chronic inflammation in the spine and of the sacroiliac joints is a key feature in Ankylosing Spondylitis (AS). A central role of CTL…
Abstract Number: 0803 • ACR Convergence 2023
IL10 Inhibits Toll-like Receptor-9-induced T Cell Receptor-mediated T Cell Activation in Macrophage Activation Syndrome
Matthew Eremita¹, Omar Geier², Joyce Hui-Yuen¹ and Matthew Taylor³, ¹Division of Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ²Sepsis Research Laboratory, Feinstein Institutes for Medical Research, Manhasset, NY, ³Division of Pediatric Critical Care, Cohen Children's Medical Center, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Gene expression pathway analyses have identified altered Toll-like receptor…
Abstract Number: 1493 • ACR Convergence 2023
Novel BCMA-CD19 Compound CAR-T (cCAR) Targets B Cells and Plasma Cells Achieving Immune Reset and Eliminates All Autoantibodies in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients Resulting in Long-Term, Medication-Free Remission
Yong Yuan¹, Shanzhi He¹, Wenli Zhang², Hongyu Zhang², Vincent DeStefano³, Masayuki Wada³, Kevin Pinz³, Greg Deener³, Yu Ma⁴, Min Wang¹, Fugui Li¹, Ming Hong¹, Chanjuan Zou¹, Mingxia Wang¹, Ling Ding¹, Yingwen Liang¹, Yupo Ma³ and Weijia Wang¹, ¹Zhongshan People’s Hospital, Zhongshan, China, ²Peking University Shenzhen Hospital, Shenzhen, China, ³iCell Gene Therapeutics Inc., Stony Brook, NY, ⁴iCAR Bio Therapeutics Ltd, Zhongshan, China
Background/Purpose: Evaluate cCAR safety in SLE, LN and autoimmune conditions. Determine whether a single dose eliminates autoantibodies with well tolerated long-term, medication-free remission in open…
Abstract Number: 2603 • ACR Convergence 2023
Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis
Christopher Redmond¹, Robert Zorc², McKella Sylvester³, Cameron Rankin⁴, Rebecca Kuan⁵, Kristina Wells⁶, Lily Dai⁷, Kaitlin Quinn⁸, Massimo Gadina⁹ and Peter Grayson¹⁰, ¹National Institutes of Health, Hagerstown, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health, Bethesda, MD, ³Colgate University, Bethesda, MD, ⁴NIAMS, NIH, Washington, DC, ⁵NIH, Bethesda, MD, ⁶University of California Davis, Bethesda, MD, ⁷NIH, Germantown, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis in adults that commonly involves the aorta and branching arteries, resulting in multiple symptoms including…
Abstract Number: 020 • 2023 Pediatric Rheumatology Symposium
Generation of Human Resident Memory T Cells in 3D Synovial Organoid Model
Margaret Chang¹, Maryrose Hahn¹, Brian Wauford¹, Rachel Blaustein², Kevin Wei² and Peter Nigrovic¹, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Most rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) patients experience episodic arthritis flares and require life-long medications to control their disease. We observed…
Abstract Number: 129 • 2023 Pediatric Rheumatology Symposium
Interrogation of STAT3 Activation in Patients with Polyarticular Juvenile Arthritis (polyJIA)
Stephanie Wood¹, Justin Branch¹, Priscilla vasquez¹, Marietta De Guzman¹, Amanda Brown², A. Carmela Sagcal-Gironella³, Saimun Singla⁴, Andrea Ramirez⁵ and Tiphanie Vogel⁵, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Hackensack University Medical Center, Hackensack, NJ, ⁴Self, Houston, TX, ⁵Baylor College of Medicine, Houston, TX
Background/Purpose: A better understanding of the pathogenesis of polyJIA is necessary to guide more effective clinical care, such as the development of data-driven approaches to…
Abstract Number: L03 • ACR Convergence 2022
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
Jay Tuttle¹, Edit Drescher², Jesus Abraham Simón-Campos³, Paul Emery⁴, Maria Greenwald⁵, Alan Kivitz⁶, Hyungmin Rha¹, Pia Yachi¹, Christina Kiley¹ and Ajay Nirula⁷, ¹Eli Lilly and Company, Indianapolis, IN, ²Csolnoky Ferenc Hospital, Veszprém, Hungary, ³Köhler & Milstein Research/Hospital Agustín O'Horán, Merida, Yucatan, Mexico, ⁴University of Leeds, Leeds, United Kingdom, ⁵Desert Medical Advances, Palm Desert, CA, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Eli Lilly, San Diego, CA
Background/Purpose: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). We hypothesized that peresolimab binding to PD-1,…
Abstract Number: 0569 • ACR Convergence 2022
Cytokine Storm Susceptibility Factors IL-18 and Cytotoxic Impairment Converge on Pathologic CD8 T-cell Hyperactivation
Emily Landy¹, Scott Canna², Paul Tsoukas³, Vinh Dang² and Jemy Varghese², ¹University of Pittsburgh, Pittsburgh, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Mounting evidence suggests partial defects in cytotoxicity-related genes may promote hyperinflammation in Macrophage Activation Syndrome (MAS) patients, who uniformly have highly-elevated IL-18. In mice,…
Abstract Number: 1167 • ACR Convergence 2022
Towards an Autologous 3D Skin-like Tissue Harboring Patient-Derived Fibroblasts, Keratinocytes, T-cells and Macrophages
Sasha Shenk¹, Jonathan Garlick¹, Lev Brown², Jamie Riesenberg², Christian Evans², Julia Jaffe Zweifach², Andrew Macklin², Tamar Abel³, Noelle Kosarek⁴, Mengqi Huang⁵, Avi Smith¹, Tammara Wood³, Gretel Torres⁶, Patricia pioli⁶ and Michael Whitfield⁷, ¹Tufts University School of Dental Medicine, Boston, MA, ²Tufts University, Boston, MA, ³Dartmouth College, Hanover, NH, ⁴Dartmouth Geisel School of Medicine, Lebanon, NH, ⁵University of Pittsburgh, Pittsburgh, PN, ⁶Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁷Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH
Background/Purpose: Scleroderma (Systemic Sclerosis; SSc) is an autoimmune disease of unknown etiology that is characterized by vascular dysfunction, fibrosis, and inflammation. A lack of human…
Abstract Number: 1734 • ACR Convergence 2022
Identification of Sjögren’s Disease-Associated T Cell Receptors Through Deep Sequencing and Single-Cell Transcriptomics
Ananth Aditya Jupudi¹, Michelle Joachims¹, Christina Lawrence¹, Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Astrid Rasmussen¹, Lida Radfar², Kiely Grundahl¹, R. Hal Scofield², Judith James¹, Joel Guthridge¹, Christopher Lessard¹, Linda F. Thompson¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren's disease (SjD) is a chronic rheumatic autoimmune disorder that primarily targets the lacrimal and salivary glands (SG) resulting in dry eyes and dry…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].